3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
14
Neoplasms
4
Lung Neoplasms
4
Advanced Solid Tumors
3
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Solid Tumor, Adult
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Noonan Syndrome
1
Neoplasms by Site
1
Mesothelioma
1
Lung Diseases
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
1
Hereditary Sensory and Autonomic Neuropathies
1
Healthy Participants
1
Carcinoma
1
Bronchial Neoplasms
1
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
1
Advanced Solid Tumor
1
Interventions
Bevacizumab
187
Fluorouracil
150
Leucovorin
135
Cetuximab
127
Irinotecan
114
Oxaliplatin
108
pembrolizumab
96
Capecitabine
82
IFL protocol
53
Panitumumab
43
Nivolumab
43
regorafenib
42
Folfox protocol
39
Gemcitabine
30
trifluridine tipiracil drug combination
27
Cisplatin
24
Carboplatin
24
atezolizumab
23
Pemetrexed
20
Paclitaxel
20
Drug Therapy
20
130-nm albumin-bound paclitaxel
17
Trastuzumab
14
encorafenib
13
Trifluridine
13
Ipilimumab
13
HMPL-013
13
tislelizumab
12
spartalizumab
11
Docetaxel
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colorectal Neoplasms
×
sotorasib
×
Clear all
NCT05198934
2026-04-27
CodeBreak300
Amgen
Phase 3
Completed
160 enrolled
1 FDA
NCT06252649
2026-04-24
CodeBreaK 301
Amgen
Phase 3
Recruiting
450 enrolled